Startseite>>Signaling Pathways>> GPCR/G protein>> Somatostatin Receptor>>DOTA-LM3 TFA

DOTA-LM3 TFA

Katalog-Nr.GC69003

DOTA-LM3 TFA ist ein Somatostatin-Rezeptor (SSTR) Antagonist. LM3 steht für p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2, welches auch ein Somatostatin-Antagonist ist. DOTA-LM3 TFA wird häufig mit Isotopenmarkierung zur in vivo Tumordiagnostik verwendet, wie z.B. 177Lu-DOTA-LM3 TFA und 68Ga-DOTA-LM3 TFA. 68Ga-DOTA-LM3 TFA hat eine gute biologische Verteilung, hohe Aufnahme im Tumor, gute tumorretinierende Eigenschaften und weniger Sicherheitsprobleme. 177Lu-DOTA-LM3 TFA kann zur Untersuchung von DOTATOC-negativen Lebermetastasen eingesetzt werden, wie z.B. bei Pankreas-NETs und weit verbreiteten Krebsthrombosen.

Products are for research use only. Not for human use. We do not sell to patients.

DOTA-LM3 TFA Chemische Struktur

Größe Preis Lagerbestand Menge
5mg
288,00 $
Auf Lager
10mg
450,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

Sample solution is provided at 25 µL, 10mM.

Chemical Properties of DOTA-LM3 TFA

Cas No. SDF
Formula C71H94ClF3N16O21S2 M.Wt 1664.18
Löslichkeit H2O : 100 mg/mL (60.09 mM; Need ultrasonic) Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of DOTA-LM3 TFA

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 600.9 μL 3.0045 mL 6.009 mL
5 mM 120.2 μL 600.9 μL 1.2018 mL
10 mM 60.1 μL 300.4 μL 600.9 μL
  • Molaritätsrechner

  • Verdünnung-Rechner

  • Molecular Weight Calculator

Gewicht
=
Konzentration
x
Inhalt
x
MW*
 
 
 
**Bei der Herstellung von Stammlösungen ist immer das chargenspezifische Molekulargewicht von

Berechnen

In vivo Formulation Calculator (Clear solution) of DOTA-LM3 TFA

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Bewertungen

Review for DOTA-LM3 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DOTA-LM3 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.